Physician profile
Ngoc Dang
NPI 1114534492
$9,878.98
in general payments reported to CMS, 2019-2025
35 companies · $3,294 in 2025
The $3,294 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $893 · 2023: $2,575 · 2024: $3,117 · 2025: $3,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,818 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,818.00 |
| Education | $168.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,676.60 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,011.68 | 2022-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $989.54 | 2022-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $596.35 | 2022-2025 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $549.58 | 2023-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $480.39 | 2022-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $471.31 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $444.67 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $402.03 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $377.26 | 2023-2025 | |
| Celgene Corporation | $295.86 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $271.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $251.01 | 2023-2025 | Vemlidy, Livdelzi |
| Lilly USA, LLC | $217.77 | 2024-2025 | Omvoh, Zepbound |
| Ironwood Pharmaceuticals, INC | $163.74 | 2022-2024 | Linzess |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $161.79 | 2024-2025 | |
| Amgen INC. | $158.56 | 2023-2024 | Evenity, Avsola, Amjevita |
| Medtronic, INC. | $156.61 | 2023 | Endoflip |
| Redhill Biopharma INC. | $156.21 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Celltrion USA INC. | $156.02 | 2024-2025 | Vegzelma, Zymfentra |
| Corium, LLC | $126.71 | 2023 | Azstarys |
| Ipsen Biopharmaceuticals, INC | $125.23 | 2024-2025 | Iqirvo, Bylvay |
| Kowa Pharmaceuticals America, INC. | $120.33 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $114.66 | 2024 | Airsupra |
| Mallinckrodt Hospital Products INC. | $83.78 | 2025 | Terlivaz |
| Merck Sharp & Dohme LLC | $71.48 | 2022-2023 | Dificid |
| Fresenius Kabi USA, LLC | $61.25 | 2023-2024 | Idacio |
| Sandoz INC. | $37.83 | 2024-2025 | Hyrimoz |
| Organon LLC | $35.19 | 2023 | Renflexis, Hadlima |
| Qol Medical, LLC | $29.51 | 2025 | Sucraid |
| Nestle Healthcare Nutrition INC. | $19.43 | 2022 | |
| Stryker Corporation | $18.40 | 2024 | Surgicount |
| Aimmune Therapeutics, INC. | $17.65 | 2025 | Zenpep |
| Vivus LLC | $15.74 | 2024 | Qsymia |
| Endogastric Solutions, INC | $13.76 | 2024 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ngoc Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.